LifeVantage Corporation Q4 2026 Earnings Call Summary
LifeVantage reported a revenue decline for Q4 2026 due to lower active account order volume and average order sizes, attributed in part to high prior-year comparables from the MindBody GLP-1 System launch. The acquisition of LoveBiome partially offset this impact. Management emphasized its differentiated science platform as a competitive advantage over traditional supplement companies. The new CEO outlined strategic priorities including improving brand narrative for consumers and enhancing digital experiences, while maintaining strong gross margins at 78%. Subscription-based revenue remained robust at over 75% of total revenue with improved customer retention metrics. The company is addressing price sensitivity by strengthening its value proposition rather than discounting. Formal guidance for fiscal 2027 was withheld as the CEO conducts a comprehensive business assessment to develop long-term growth strategies. Management expects continued pressure in H1 FY2027 but anticipates improvement from Q3 onward.
Topics: earnings gross margins revenue decline strategic priorities